Zardo P, Zhang R, Wiegmann B, Haverich A, Fischer S
Department of Thoracic Surgery and Lung Assist, Klinikum Ibbenbüren, Ibbenbüren, Germany.
Thorac Cardiovasc Surg. 2011 Feb;59(1):40-4. doi: 10.1055/s-0030-1250499. Epub 2011 Jan 17.
We sought to analyze the efficacy of a bovine pericardial patch (PeriGuard®) for diaphragmatic repair.
Seven consecutive patients (6 males, median age 56 years) scheduled for diaphragmatic resection and/or repair were enrolled in this study. In all cases diaphragmatic repair was performed with a PeriGuard Repair Patch® (Synovis, St. Paul, MN, USA). At follow-up (median: 12 months; range: 6-18 months), quality of life, signs of reherniation and incorporation of mesh were assessed through clinical examination, blood samples and CT or MRT scan.
Diagnosis on admission included sarcoma (n = 2), mesothelioma (n = 1), squamous cell carcinoma (n = 1), parachordoma (n = 1) and large congenital or posttraumatic herniation (n = 2). At follow-up successful diaphragmatic repair with no signs of reherniation, graft dehiscence or seroma formation was confirmed for all patients. Recorded inflammatory markers [C-reactive protein (CRP), white blood cell count (WBC) and procalcitonin (PCT)] reached their peak values between postoperative day (POD) 4 and POD 7. Values ranged from 122-282 mg/L for CRP, 0.4-4.6 µg/L for PCT and 6.2-15.6 Tsd/µL for WBC. Overall oncological results were good and 5 out of 6 survivors reported a fully reestablished quality of life.
We consider the PeriGuard Repair Patch® a viable alternative to synthetic materials for diaphragm replacement. Moreover, we advise carrying out cautious follow-up in patients undergoing extensive oncological resection to learn more about the biological behavior of the bovine PeriGuard Repair Patch® after diaphragmatic repair.
我们试图分析牛心包补片(PeriGuard®)用于膈肌修复的疗效。
本研究纳入了7例连续安排进行膈肌切除和/或修复的患者(6例男性,中位年龄56岁)。所有病例均使用PeriGuard修复补片(Synovis,美国明尼苏达州圣保罗)进行膈肌修复。在随访时(中位时间:12个月;范围:6 - 18个月),通过临床检查、血液样本以及CT或磁共振成像扫描评估生活质量、再疝形成迹象和补片融合情况。
入院诊断包括肉瘤(n = 2)、间皮瘤(n = 1)、鳞状细胞癌(n = 1)、副脊索瘤(n = 1)以及大型先天性或创伤后疝(n = 2)。随访时确认所有患者膈肌修复成功,无再疝形成、移植物裂开或血清肿形成的迹象。记录的炎症标志物[C反应蛋白(CRP)、白细胞计数(WBC)和降钙素原(PCT)]在术后第4天至第7天达到峰值。CRP值范围为122 - 282 mg/L,PCT值范围为0.4 - 4.6 μg/L,WBC值范围为6.2 - 15.6千/微升。总体肿瘤学结果良好,6名幸存者中有5名报告生活质量完全恢复。
我们认为PeriGuard修复补片是用于膈肌替代的合成材料的可行替代品。此外,我们建议对接受广泛肿瘤切除的患者进行谨慎随访,以更多地了解牛PeriGuard修复补片在膈肌修复后的生物学行为。